ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States
See the original post here:
Outcomes of Unselected Recipients of Sirolimus-Eluting Stents: The Cypher® Stent U.S. Post-Marketing Surveillance Registry